Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
14 participants
INTERVENTIONAL
2022-09-15
2023-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acupuncture for the Treatment of Rheumatoid Arthritis
NCT00404443
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
NCT00748254
Acupressure for Fatigue in Systemic Lupus Erythematosus
NCT03200548
Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient
NCT02020668
Effects of Pulsed Magnetic Pads on Rheumatoid Arthritis Symptoms in Postmenopausal Women
NCT00110565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acupressure
The self-acupressure intervention will be delivered using the modified MeTime Acupressure mobile application (App) in addition to in-person or virtual instruction via study staff.
Acupressure
The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.
In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acupressure
The MeTime Acupressure app will be loaded onto computer tablets or smart phones by the participants. Participants will also receive an AcuWand to be used in association with the acupressure app to help participants apply the correct amount of pressure to acupoints. There are 9 acupressure points, totaling 27 minutes of stimulation per day. Participants will perform daily acupressure for a total of six weeks.
In addition all participants will complete a battery of validated questionnaires before, during and after completion of treatment intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Methotrexate (Trexall, Rheumatrex)
* Hydroxychloroquine (Plaquenil)
* Sulfasalazine (Azulfadine)
* Leflunomide (Arava)
* Tocilizumab (Actemra)
* Tumor necrosis factor inhibitor (TNFi), including:
Adalimumab (Humira) Etanercept (Enbrel) Certolizumab pegol (Cimzia) Golimumab (Simponi) Infliximab (Remicade)
* Abatacept (Orencia)
* Tocilizumab (Actemra)
* Janus kinase inhibitor (JAKi), including:
Tofacitinib (Xeljanz) Baracitinib (Olumiant) Upadacitinib (Rinvoq)
o Rituximab (Rituxan)
Exclusion Criteria
* Do not speak or read English
* Do not have access to smart phone with access to mobile applications
* Severe psychiatric disorders including history of substance abuse disorders,
* Individuals on high doses of opioids (over 100 oral morphine equivalents)
* Taking blood thinners, including warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
* Thrombocytopenia (low platelet count)
* Expecting to receive surgery within the next year for their RA
* Pregnancy or breast feeding, or anticipate pregnancy in next year,
* Actively applying for disability or compensation, or actively involved in litigation.
* Anything at the discretion of the principal investigator or study team
25 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Murphy
House Officer, Internal Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Murphy, MD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUM00206002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.